@EHMETSEEN @diabeteSEEN @ObesitySeen @diabeteSEEN

Microdosing instructions for tirzepatide with multi‑dose Mounjaro KwikPens. Details of how to count clicks to achieve an accurate dose. We still need real‑world safety and efficacy data before treating this as standard care. onlinelibrary.wiley.com/doi/…

Presented at #ADASciSessions: In a phase 3 trial involving adults with obesity but without diabetes, the glucagon receptor–GLP-1 receptor dual agonist survodutide led to significantly greater reductions in body weight than placebo. Full SYNCHRONIZE-1 trial results: nej.md/4x7Tafs @ADA_DiabetesPro

🔴 SYNCHRONIZE-MASLD @NatureMedicine Survodutida 6,0 mg semanal en obesidad MASLD de riesgo (fase 3, 48 sem): 📉 ≥30% reducción de grasa hepática (MRI-PDFF): 84,2% vs 24,3% placebo 🫀 −12,2% de peso vs −1,0% 🔬 61% normalizó la grasa hepática (<5%) Mejoras además en cT1, ALT, AST, rigidez por VCTE y perfil cardiometabólico. Sin DILI, pancreatitis ni cáncer adjudicados. Doble agonismo GCGR/GLP-1: efecto hepático más allá de la pérdida de peso. 🔗 nature.com/articles/s41591-0… #ADA2026 #ADAScisessions

COMPETE SWITCH study People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide 2.5/5 mg , in real-world data #ada2026 #adascisessions ml-eu.globenewswire.com/Reso…

Retatrutide in adults with obesity over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25

🚨TRANSCEND-T2D-1 full paper is out in Lancet. Retatrutide in T2D with diet and exercise. 40 weeks. Presenting at ADA 2926. ▪️Treatment regimen estimand: 1.94% reduction in A1C, 15.3% WL (Starting A1C of 7.9-8% average) ▪️Importantly, it doesn’t appear any of the arms had fully plateaued yet, but 4mg may have been getting there. ▪️53-59% females in retatrutide treatment arms, starting BMIs around 35-36 ▪️Treatment discontinuations due to adverse events: 5% ▪️Nausea 26%, vomiting 18% (placebo had 4% and 2% respectively)

We could prevent 55% of complex disease if we can treat underlying obesity. What an unmet need and tremendous potential. Dr. Sattar #ADASciSessions

Nuevo análisis preespecificado del ensayo FIND-CKD: El rol de la Finerenona en la Enfermedad Renal Crónica por Glomerulopatías. 🧬. 🧵👇🏻 doi: 10.1001/jama.2026.9923 @SENefrologia @SLANH_ @SLANHJoven @GlomConILA @JonathanNefro @PepaSolerR @jorgericof @PerlaZambrano

Dicen que en la #ADA2026 los póster se cuelgan todos apaisados 😢... pero en vertical no quedan tan mal, ¿verdad?. Llaman más la atención 😅.

Systematic review and meta-analysis of weight loss with GLP-1 agonists. onlinelibrary.wiley.com/doi/…

Identification of the acute pancreas-independent actions of GIP vs. GLP-1 in humans-note the profound actions of GIP on HR and DBP dom-pubs.pericles-prod.liter…

El fin de la era "pesocéntrica" en la obesidad. ⚕️ La revisión clínica de The Lancet Diabetes & Endocrinology (2026) consolida a los coagonistas de incretinas como terapias sistémicas modificadoras de la enfermedad, más allá del adipocito. 🧵👇 doi.org/10.1016/S2213-8587(2… @SociedadSeedo @Diabetes_SEMI @redGDPS @ObesitySeen @SACcardiometab1 @IcyfaSemi @endocatracha @PerlaZambrano @SENefrologia @SLANH_ @fjavesc @albertlecube

🔬 5 major obesity medicine updates from #ECO2026 — here’s what you need to know 🧵 1/ SURMOUNT-MAINTAIN — Zepbound works, but only if you stay on it. Full dose → maintained ALL weight loss Dropped to 5mg → regained ~12 lbs Switched to placebo → regained up to 43 lbs 67% of placebo patients needed rescue therapy 😳 2/ ATTAIN-MAINTAIN — Oral Foundayo (orforglipron) after Wegovy/Zepbound preserved most weight loss vs. placebo. Transition drugs are viable. 💊 3/ High-dose Wegovy 7.2mg — Early responders lost an average of 27.7% body weight by week 72. Early response = strong predictor of outcomes. 📈 4/ Wegovy PILL (oral semaglutide 25mg) — Early responders lost 21.6% body weight by week 64 vs. 2.7% placebo. An oral GLP-1 that actually works. 🙌 5/ Body composition data — ~84% of weight lost was fat mass. Visceral fat ↓ >30%. Muscle function was preserved. This is the data we needed. 💪 🎯 The big takeaway: Long-term treatment, dose flexibility, and new oral options are shaping the future of obesity care. Personalized = sustainable = best results. #ObesityMedicine #GLP1 #Tirzepatide #Semaglutide #ECO2026 #MedTwitter

Hasta que Miguel Bosé no dé su opinión sobre el hantavirus estamos hablando sin saber.

Con enfermedad renal crónica tratada con iSGLT2, añadir finerenona, comparado a no hacerlo; se asoció a ↓74% el riesgo de perder >30% de TFGe, mayor beneficio en aquellos que venían con deterioro más rápido. Seguimiento de 18 meses Diabetes Obes Metab 2026 10.1111/dom.70821

These validated, publicly available #polygenic risk scores (PRSs) can improve risk stratification for type 2 #diabetes onset and complications across diverse ancestries, supporting their further evaluation in clinical settings thelancet.com/journals/landi… #T2D #genetics #OpenAccess

Si ves esto en el supermercado: huye. “GLP-1 friendly” en un producto ultraprocesado no significa nada clínicamente. Es marketing puro. Lo que SÍ necesitas si recibes tratamiento con GLP-1: ✅ Proteína en cada comida (1,2-1,5g/kg) ✅ Verdura para llenar el plato ✅ Fibra: fruta, verdura, alimentos integrales, legumbres ✅ Hidratación ✅ Seguimiento especializado Sin olvidarte de entrenar 🏋️!

New @Nature A quintuple [GLP-1 4 other] receptor agonist drug that exceeds effects of the dual receptor (GLP-1 and GIP, tirzepatide) in the experimental model vs diabetes and obesity (in case you thought a dual receptor was max effect, as also seen with retatrutide, a triple receptor agonist) nature.com/articles/s41586-0…

🚨Inpatient safety, effectiveness of SGLT2 inh. and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study 🆓🇪🇸 🏥 979, managed either on oral antidiabetic drugs (with or without insulin) under a start–stop protocol (Group A) or with insulin-only therapy (Group B) 📊 Group A was associated with a ⬇️ 47% risk of severe AE (level 2–3 hypoglycaemia or DKA)(aOR 0.53) and after PS matching (OR 0.31). 📉Group A had a lower median daily glucose level (153 mg/dL vs. 179 mg/dL), lower glycaemic variability and a shorter hospital stay (5 days vs. 7 days) ☠️No differences 🚩What is new? • In hospital non-insulin glucose-lowering therapies reduce hypoglycaemia risk. • Achieve superior glycemic control with reduced variability. • Shorten hospital stay without increased ICU admission or mortality. 🚩How might this study influence clinical practice? Our proof of concept suggests reevaluating standard practices for early in-hospital SGLT2i/GLP-1RA use. 👉🏻evidence supporting a transition from the traditional practice of therapeutic deferral to a more proactive inpatient management strategy 👉🏻hospitalization represents a strategic opportunity to initiate SGLT2 inh. and GLP-1RAs, moving beyond acute stabilization toward the optimization of long-term cardiometabolic care. @isabial_iis @GVAsanitat @BioMedCentral @SpringerNature @diabeteSEEN @SEDiabetes @secardiologia @SENefrologia @Sociedad_SEMI @SEMERGENap @semfyc @fjavesc @cristinatejerap @CristobMorales @DrTinahones @ketandhatariya @ADA_DiabetesPro @EASDnews @EASDelearning @TheAACE @ThaerIdrees @InzucchiSE @AnnePetersMD @EricTopol link.springer.com/content/pd…